Activated protein C resistance test using factor VIII-deficient plasma: A new approach to the venous thrombotic risk?

Elisabeth André; Marie Hacquard; Yveline Alnot; Emmanuel de Maistre; Thomas Lecompte

doi:10.1160/TH06-11-0661

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(03): 693-694
DOI: 10.1160/TH06-11-0661

Letters to the Editor

Schattauer GmbH

Activated protein C resistance test using factor VIII-deficient plasma: A new approach to the venous thrombotic risk?

Elisabeth André

¹Haematology Laboratory, University Hospital of Nancy, V andoeuvre les Nancy, France

,

Marie Hacquard

¹Haematology Laboratory, University Hospital of Nancy, V andoeuvre les Nancy, France

²INSERM U734,V andoeuvre les Nancy, France

,

Yveline Alnot

¹Haematology Laboratory, University Hospital of Nancy, V andoeuvre les Nancy, France

,

Emmanuel de Maistre

¹Haematology Laboratory, University Hospital of Nancy, V andoeuvre les Nancy, France

,

Thomas Lecompte

¹Haematology Laboratory, University Hospital of Nancy, V andoeuvre les Nancy, France

²INSERM U734,V andoeuvre les Nancy, France

› Author Affiliations

Abstract

Full Text

References

References
1 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : prediction of a cofacteur to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
2 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3 Jorquera JI, Montoto JM, Fernandez MA. et al. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
4 Guerrero F, Arnaud C, Nguyen F. et al. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non carriers of the factor V Leiden mutation. Thromb Haemost 2006; 95: 728-734.
5 Regnault V, De Maistre E, Geshier C. et al. A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995; 73: 1780.
6 Henkens C, Born V, van der Meer J. Lowered APCsensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1197-1207.
7 Koster T, Blann AD, Briet E. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
8 Kraaijenhagen RA, Anker PS, Koopman MM. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
9 O’Donnell J, Mumford AD, Mannig RA. et al. Elevation of FVIII :C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13.
10 Soria JM, Almasy L, Souto JC. et al. A new locus on chromosome 18 that influences normal variant in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-167.
11 Nossent AY, Eikenboom JC, Vos HL. et al. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost 2006; 95: 942-948.
12 Roelse JC, Foopman M, Buller HR. et al. Absence of mutations at the activated protein C cleavage site of factor VIII in 125 patients with venous thrombosis. Brit J Haematol 1996; 92: 740-743.
13 Brummer J, Groth J, Flayeh R. et al. Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb Haemost 2002; 87: 170-171.